Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar;6(2):69-82.
doi: 10.1177/1758834013517413.

Relapsed small cell lung cancer: treatment options and latest developments

Nobuhiro Asai  1 , Yoshihiro Ohkuni  2 , Norihiro Kaneko  2 , Etsuro Yamaguchi  3 , Akihito Kubo  3
Affiliations
Review

Relapsed small cell lung cancer: treatment options and latest developments

Nobuhiro Asai et al. Ther Adv Med Oncol. 2014 Mar.

Abstract

According to recent analyses, there was a modest yet significant improvement in median survival time and 5-year survival rate of limited stage small cell lung cancer (SCLC) in North America, Europe, Japan and other countries over the last 30 years. The median survival time of limited stage SCLC is 15-20 months and 5-year survival rate is 15% or less. In terms of extensive stage SCLC, a median survival time of 9.4-12.8 months and 2-year survival of 5.2-19.5% are still disappointing. Despite being highly sensitive to first-line chemotherapy and radiotherapy treatments, most patients with SCLC experience relapse within 2 years and die from systemic metastasis. While several clinical trials of cytotoxic chemotherapies and molecular targeting agents have been investigated in the treatment of relapsed SCLC, none showed a significant clinical activity to be able to exceed topotecan as second-line chemotherapy. There are problematic issues to address for relapsed SCLC, such as standardizing the treatment for third-line chemotherapy. Topotecan alone was the first approved therapy for second-line treatment for relapsed SCLC. Amrubicin is a promising drug and a variety of trials evaluating its efficacy have been carried out. Amrubicin has shown superiority to topotecan in a Japanese population, but was not superior in a study of western patients. There are some controversial issues for relapsed SCLC, such as treatment for older patients, third-line chemotherapy and efficacy of molecular targeting therapy. This article reviews current standard treatment, recent clinical trials and other topics on relapsed SCLC.

Keywords: chemotherapy; refractory relapse; sensitive relapse; small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors have no financial or personal relationships with other people or organizations that could inappropriately influence our work.

References

    1. Abrams T., Lee L., Murray L., Pryer N., Cherrington J. (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471–478 - PubMed
    1. Allen J., Moon J., Gadgeel S., Kelly K., Mack P., Saba H., et al. (2012) SWOG 0802: a randomized phase II trial of weekly topotecan with and without AVE0005 (aflibercept) in patients with platinum-treated extensive-stage small cell lung cancer (E-SCLC). 2012 ASCO Annual Meeting. J Clin Oncol 30(Suppl.): abstract 7005. - PMC - PubMed
    1. Ando M., Kobayashi K., Yoshimura A., Kurimoto F., Seike M., Nara M., et al. (2004) Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 44: 121–127 - PubMed
    1. Ardizzoni A. (2004) Topotecan in the treatment of recurrent small cell lung cancer: an update. Oncologist 9(Suppl. 6): 4–13 - PubMed
    1. Ardizzoni A., Antonelli G., Ricci S., Frasci G., Rinaldi M., Boni L., et al. (2000) Ambamustine in the second-line treatment of patients with small-cell lung cancer: a phase II Fonicap study. Am J Clin Oncol 23: 22–25 - PubMed